Takeda director files initial Form 3

TAKEDA PHARMACEUTICAL CO LTD director files initial ownership report.

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD director files initial ownership report. Kimura Koichiro filed a Form 3 as a director of Takeda Pharmaceutical, which is an initial statement of beneficial ownership required when someone becomes an insider. This filing does not report any share purchases, sales, or other transactions.

Key Terms

Form 3, initial statement of beneficial ownership, insider

3 terms

Form 3 regulatory

"Kimura Koichiro filed a Form 3 as a director of Takeda Pharmaceutical"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

initial statement of beneficial ownership regulatory

"which is an initial statement of beneficial ownership required when someone becomes an insider"

An initial statement of beneficial ownership is the first regulatory filing an insider or large investor submits to disclose the amount of a company's stock they control or benefit from. It matters to investors because it reveals who has significant influence over a company—like showing who’s holding the cards—and helps track potential conflicts of interest, insider motives, and future buying or selling that can move the stock price.

insider regulatory

"required when someone becomes an insider"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Takeda (TAK) Form 3 filing for Kimura Koichiro show?

The Form 3 for Kimura Koichiro is an initial statement of beneficial ownership as a director of Takeda Pharmaceutical. It reports that no share purchases, sales, or other insider transactions are included in this filing.

Did Kimura Koichiro buy or sell Takeda (TAK) shares in this Form 3?

No, the Form 3 for Kimura Koichiro shows zero buy, sell, gift, exercise, tax withholding, or restructuring transactions. It serves only as an initial ownership report without reporting any trades.

What is the purpose of this Takeda (TAK) Form 3 filing?

This Form 3 serves as an initial disclosure of insider status for director Kimura Koichiro at Takeda Pharmaceutical. It is a regulatory requirement and does not by itself indicate any change in share ownership through trading activity.

Does the Takeda (TAK) Form 3 for Kimura Koichiro include derivative positions?

The Form 3 summary shows no derivative transactions and an empty derivative position list. This means the filing does not report any options, warrants, or other derivative holdings or exercises for Kimura Koichiro.

Is there any trading signal from the Takeda (TAK) Form 3 by Kimura Koichiro?

This Form 3 provides no trading signal, because it shows no insider purchases, sales, or derivative exercises. It is purely an initial ownership statement reflecting regulatory disclosure when someone becomes a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 11:32 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kimura Koichiro

(Last) (First) (Middle)

1-1, NIHONBASHI-HONCHO 2-CHROME

CHUO-KU, TOKYO

(Street)

TOKYO 1038668

(City) (State) (Zip)

JAPAN

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/24/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Kate Huleatt, by power of attorney, for Kimura Koichiro	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)